The effect of a once daily evening dose of atomoxetine (ATX) on ADHD [attention-deficit hyperactivity disorder]-related insomnia in children and adolescents

Trial Profile

The effect of a once daily evening dose of atomoxetine (ATX) on ADHD [attention-deficit hyperactivity disorder]-related insomnia in children and adolescents

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Insomnia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2008 The expected completion date for this trial is now 1 Jun 2009 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top